OXIDE Corp. (JP:6521) has released an update.
OXIDE Corporation reported a strong first quarter performance in its healthcare business, attributing the success to accelerated customer demand, especially in cancer diagnosis PET scanners. The company is expanding its market share with existing customers, developing relationships with new ones, and innovating with new materials for single crystals used in brain PET scanners. They expect continued revenue growth as sales to new customers commence from the second quarter onwards.
For further insights into JP:6521 stock, check out TipRanks’ Stock Analysis page.
